Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Keith Ridel

Neurology with Special Qualifications in Child Neurology Indianapolis, IN Medical Doctor

NPI 1053528935 CMS profile 228757

7250 Clearvista Dr Ste 225, Indianapolis, IN 46256

Open in the dashboard

General payments

$110,067

1,969 records reported · program years 2019–2025

Research payments

$5,379

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$346,978 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Keith Ridel of Indianapolis, IN is reported in the CMS Open Payments database as having received $110,067 across 1,969 general payments and $5,379 in research payments paid to them. Separately, studies naming them as principal investigator received $346,978 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,372 211
2024 General $7,343 302
2024 Research $1,995 1
2023 General $5,996 288
2022 General $6,019 310
2022 Research $297 1
2021 General $5,381 281
2021 Research $1,264 2
2020 General $2,889 227
2020 Research $382 2
2019 General $77,068 350
2019 Research $1,440 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keith Ridel
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Keith Ridel were reported at $5,372. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Keith Ridel Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $77,068 $262 $68–$1,313 $163
2020 $2,889 $188 $46–$1,222 $114
2021 $5,381 $183 $45–$1,356 $132
2022 $6,019 $229 $72–$1,177 $149
2023 $5,996 $269 $93–$1,195 $160
2024 $7,343 $300 $98–$1,428 $164
2025 $5,372 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eisai Inc. $74,085 167 payments
  2. AbbVie, Inc. $4,978 237 payments
  3. UCB, Inc. $3,894 256 payments
  4. Jazz Pharmaceuticals Inc. $1,905 49 payments
  5. SK Life Science, Inc. $1,891 64 payments
  6. Novartis Pharmaceuticals Corporation $1,440 110 payments
  7. LivaNova USA, Inc. $1,315 29 payments
  8. Biohaven Pharmaceuticals, Inc. $1,226 56 payments
  9. Pfizer Inc. $1,147 62 payments
  10. Neurocrine Biosciences, Inc. $993 41 payments
  11. Other $17,194 898 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $50,019 42 payments
  2. Food and Beverage $39,480 1,873 payments
  3. Travel and Lodging $15,186 50 payments
  4. Consulting Fee $5,370 3 payments
  5. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. Fycompa $67,260 154 payments
  2. QULIPTA $2,659 109 payments
  3. Briviact $2,488 211 payments
  4. Epidiolex $2,242 59 payments
  5. NURTEC ODT Primary Care $2,062 115 payments
  6. UBRELVY $1,690 109 payments
  7. NURTEC ODT Pain $1,098 59 payments
  8. AIMOVIG $1,037 26 payments
  9. VALTOCO $923 41 payments
  10. BOTOX $917 38 payments
  11. Other $21,490 1,131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Arbor Pharmaceuticals, Inc. $2,704 3 payments
  2. Eli Lilly and Company $2,674 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

157

Median for Neurology: 833

Drug cost

$190,441

Median for Neurology: $202,670

Branded share of claims

29.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 12 $140,066
Epidiolex Cannabidiol (Cbd) Brand 17 $43,661
Lacosamide Generic 27 $4,282
Levetiracetam Generic 31 $992
Oxcarbazepine Generic 15 $917
Clopidogrel Clopidogrel Bisulfate Brand 18 $236
Atorvastatin Calcium Generic 26 $178
Lamotrigine Generic 11 $110

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$109,253

Medicare's payments for the services billed

Medicare patients

482

Average age 72

Services billed

1,620

249 women, 233 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Chronic kidney disease 47%
Depression 47%
Diabetes 45%
Ischemic heart disease 45%
Heart failure 37%
Atrial fibrillation 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 46 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Briviact
$755 — —
QULIPTA
$643 — —
Apokyn
$459 — —
Epidiolex
$290 17 —
NURTEC ODT
$263 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 46 with Patron

Records

1,976 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record